Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 14/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507606 | 0.85 | WDR5 (0.37) | WDR5HTR2AHTR2CHTR2BEPHX2 | |
| Hydrochloric Acid SCHEMBL10476178 | 0.83 | WDR5 (0.35) | WDR5HTR2AHTR2CHTR2BPDE5A | |
| SCHEMBL508106 | 0.83 | HTR2A (0.38) | WDR5HTR2AHTR2CHTR2BPDE5A | |
| SCHEMBL10230571 | 0.83 | WDR5 (0.36) | WDR5HTR2AHTR2CHTR2BEPHX2 | |
| SCHEMBL507020 | 0.82 | WDR5 (0.36) | WDR5HTR2AHTR2CHTR2BEPHX2 | |
| SCHEMBL507021 | 0.82 | WDR5 (0.36) | WDR5HTR2AHTR2CHTR2BEPHX2 | |
| SCHEMBL10274906 | 0.82 | ALDH1A1 (0.37) | WDR5HTR2AHTR2CHTR2BEPHX2 | |
| SCHEMBL508081 | 0.82 | PARP1 (0.40) | WDR5 | |
| SCHEMBL10230576 | 0.82 | WDR5 (0.42) | WDR5HTR2AHTR2CHTR2BEPHX2 | |
| SCHEMBL10277924 | 0.82 | WDR5 (0.35) | WDR5HTR2AHTR2CHTR2BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | WDR5 815/4885HTR2A 4/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.